Orano Med
Amy Wong, PhD, is a seasoned chemist with extensive experience in peptide chemistry. Currently serving as a Senior Peptide Chemist at Orano Med since June 2017, Amy has progressed through various roles, including Peptide Chemist and Postdoctoral Researcher. Prior to this, Amy contributed as a Graduate Research Assistant at Stony Brook University from August 2011 to January 2017 and gained foundational research experience as an Undergraduate Research Assistant at Adelphi University from January 2010 to August 2011. Academically, Amy holds a PhD in Chemistry from Stony Brook University, earned in 2016, and a Bachelor of Science in Chemistry from Adelphi University, completed in 2011.
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.